Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A novel assay for screening WIP1 phosphatase substrates in nuclear extracts

R. Storchova, K. Burdova, M. Palek, RH. Medema, L. Macurek

. 2021 ; 288 (20) : 6035-6051. [pub] 20210527

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK Free Medical Journals from 2005 to 1 year ago
Medline Complete (EBSCOhost) from 2005-01-01 to 1 year ago
Wiley Free Content from 2005 to 1 year ago

Upon exposure to genotoxic stress, cells activate DNA damage response (DDR) that coordinates DNA repair with a temporal arrest in the cell cycle progression. DDR is triggered by activation of ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related protein kinases that phosphorylate multiple targets including tumor suppressor protein tumor suppressor p53 (p53). In addition, DNA damage can activate parallel stress response pathways [such as mitogen-activated protein kinase p38 alpha (p38)/MAPK-activated protein kinase 2 (MK2) kinases] contributing to establishing the cell cycle arrest. Wild-type p53-induced phosphatase 1 (WIP1) controls timely inactivation of DDR and is needed for recovery from the G2 checkpoint by counteracting the function of p53. Here, we developed a simple in vitro assay for testing WIP1 substrates in nuclear extracts. Whereas we did not detect any activity of WIP1 toward p38/MK2, we confirmed p53 as a substrate of WIP1. Inhibition or inactivation of WIP1 in U2OS cells increased phosphorylation of p53 at S15 and potentiated its acetylation at K382. Further, we identified Deleted in breast cancer gene 1 (DBC1) as a new substrate of WIP1 but surprisingly, depletion of DBC1 did not interfere with the ability of WIP1 to regulate p53 acetylation. Instead, we have found that WIP1 activity suppresses p53-K382 acetylation by inhibiting the interaction between p53 and the acetyltransferase p300. Newly established phosphatase assay allows an easy comparison of WIP1 ability to dephosphorylate various proteins and thus contributes to identification of its physiological substrates.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003575
003      
CZ-PrNML
005      
20220127150105.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/febs.15965 $2 doi
035    __
$a (PubMed)33982878
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Storchova, Radka $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
245    12
$a A novel assay for screening WIP1 phosphatase substrates in nuclear extracts / $c R. Storchova, K. Burdova, M. Palek, RH. Medema, L. Macurek
520    9_
$a Upon exposure to genotoxic stress, cells activate DNA damage response (DDR) that coordinates DNA repair with a temporal arrest in the cell cycle progression. DDR is triggered by activation of ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related protein kinases that phosphorylate multiple targets including tumor suppressor protein tumor suppressor p53 (p53). In addition, DNA damage can activate parallel stress response pathways [such as mitogen-activated protein kinase p38 alpha (p38)/MAPK-activated protein kinase 2 (MK2) kinases] contributing to establishing the cell cycle arrest. Wild-type p53-induced phosphatase 1 (WIP1) controls timely inactivation of DDR and is needed for recovery from the G2 checkpoint by counteracting the function of p53. Here, we developed a simple in vitro assay for testing WIP1 substrates in nuclear extracts. Whereas we did not detect any activity of WIP1 toward p38/MK2, we confirmed p53 as a substrate of WIP1. Inhibition or inactivation of WIP1 in U2OS cells increased phosphorylation of p53 at S15 and potentiated its acetylation at K382. Further, we identified Deleted in breast cancer gene 1 (DBC1) as a new substrate of WIP1 but surprisingly, depletion of DBC1 did not interfere with the ability of WIP1 to regulate p53 acetylation. Instead, we have found that WIP1 activity suppresses p53-K382 acetylation by inhibiting the interaction between p53 and the acetyltransferase p300. Newly established phosphatase assay allows an easy comparison of WIP1 ability to dephosphorylate various proteins and thus contributes to identification of its physiological substrates.
650    _2
$a acetylace $7 D000107
650    _2
$a adaptorové proteiny signální transdukční $x genetika $x metabolismus $7 D048868
650    _2
$a biotest $x metody $7 D001681
650    _2
$a nádory kostí $x genetika $x metabolismus $x patologie $7 D001859
650    _2
$a buněčné jádro $x genetika $x metabolismus $7 D002467
650    _2
$a poškození DNA $7 D004249
650    _2
$a oprava DNA $7 D004260
650    _2
$a lidé $7 D006801
650    _2
$a osteosarkom $x genetika $x metabolismus $x patologie $7 D012516
650    _2
$a fosforylace $7 D010766
650    _2
$a interakční proteinové domény a motivy $7 D054730
650    _2
$a proteinfosfatasa 2C $x genetika $x metabolismus $7 D000071636
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Burdova, Kamila $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Palek, Matous $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Medema, René H $u Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, The Netherlands
700    1_
$a Macurek, Libor $u Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
773    0_
$w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 288, č. 20 (2021), s. 6035-6051
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33982878 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150101 $b ABA008
999    __
$a ok $b bmc $g 1751131 $s 1154724
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 288 $c 20 $d 6035-6051 $e 20210527 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...